# A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

> **NCT01732757** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 157 (actual)

## Conditions studied

- Conjunctivitis, Allergic

## Interventions

- **DRUG:** Alcaftadine 0.25%
- **DRUG:** Olopatadine 0.2%
- **DRUG:** dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%

## Key facts

- **NCT ID:** NCT01732757
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732757, "A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT01732757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*